$191 Billion and Counting: Inside Healthcare Private Equity's Record Year — And Why Dental Is the #2 Hottest Sector

Healthcare private equity hit an all-time record of $191 billion in deal value during 2025 — shattering the previous peak of $151 billion in 2021 and signaling that the age of mega-consolidation in medical services has only just begun. With approximately 445 buyouts announced last year, capital is flooding into healthcare at levels that dwarf any other sector. But the geography of that capital is revealing. While health IT accounted for 151 deals and outpatient care for 148, dental captured 149 deals — making it the second-most active category in healthcare PE. That is not incidental. Dental is experiencing a structural transformation being actively accelerated by $200-250 billion in healthcare-allocated dry powder, much of it under acute deployment pressure. For practice owners, operators, and investors, understanding this capital wave is essential to survival.

The Money Wall: Why $191 Billion Matters More Than It Appears

The year-over-year trajectory reveals the severity of capital accumulation. Healthcare PE deal value has surged from $66 billion in 2020 to $151 billion in 2021, compressed to $90 billion in 2022 as interest rates rose, contracted further to $60 billion in 2023, rebounded to $115 billion in 2024, and exploded to $191 billion in 2025. That is not a recovery. That is an acceleration. The global PE dry powder stands at approximately $1.2-1.3 trillion, with healthcare capturing $200-250 billion of allocated capital. That is roughly 18% of all institutional PE capital sitting on the sidelines, hunting for targets.

The pressure to deploy is intense. Approximately 25% of PE dry powder is now 4 or more years old — capital that is approaching the back end of its fund lifecycle. For GPs managing multi-billion-dollar healthcare funds, sitting with idle capital costs fees, disappoints LPs, and creates performance drag. That urgency drives two behaviors: more aggressive valuations on premium targets and an expanding appetite for secondary deals and sponsor-to-sponsor transactions.

The secondary market itself hit records. Sponsor-to-sponsor deals exceeded 150 transactions and $120 billion in aggregate value during 2025 — a direct reflection of existing PE platforms being rolled, recapitalized, or sold to larger sponsors. When incumbent PE owners cash out to new PE owners, buyout multiples remain high and deployment accelerates. The deal market is efficiently recycling capital from smaller firms into mega-platforms while maintaining valuation floors.

Why Dental Is #2 — And Why That Matters

Dental captured 149 PE-backed deals in 2025, trailing only health IT's 151. That alignment is not accidental. Both sectors are highly fragmented, operator-friendly, and capable of rapid add-on acquisition models. Unlike hospital systems, which require regulatory approval and cultural integration, dental practices close in weeks. Unlike medtech, which demands technical talent and IP, dental is operationally scalable through standardized playbooks.

The structure reveals the pattern. Approximately 95% of dental PE deals in 2025 were add-on acquisitions — defined as one DSO acquiring individual practices or smaller groups to fold into an existing platform. Add-on acquisitions operate at much lower multiples than platform acquisitions: 5-8x EBITDA versus 9-11x for DSO platforms seeking to enter new geographies or service lines. A single $200 million platform deal might sit alongside 20-30 add-on acquisitions at a tenth of the size, but each contributing similar acquisition fee economics for the PE sponsor and creating incremental revenue consolidation.

The DSO market penetration forecast tells the story of where capital sees opportunity. As of 2022, DSOs controlled approximately 23% of the U.S. dental market by patient volume. That percentage is projected to reach 39% by 2026 — a 70% increase in market share in four years. With 130+ PE-backed DSOs now operating in the United States and consolidation rates accelerating, the funnel for add-on deals is essentially unlimited. As long as there are independent or semi-independent practices generating positive EBITDA, there is a DSO buyer.

Valuation ceilings are real but permeable. A DSO platform trading at 9-11x EBITDA is considered premium. Add-ons at 5-8x represent value capture. The practical ceiling, where PE sponsors will rarely venture, sits around 12x EBITDA on high-growth platforms with exceptional unit economics. But that ceiling is elastic — driven not by fundamental value but by dry powder deployment urgency and competition between sponsors for dealflow.

The Public-to-Private Pipeline: When Wall Street Meets Consolidation

Parallel to the DSO buyout wave, PE is executing a separate strategy: taking established public healthcare companies private at distressed valuations. The logic is simple: public market volatility creates opportunities to acquire quality assets at discounts to intrinsic value.

Walgreens became the poster child. The company was taken private for $23.7 billion, a deal motivated by stock that had declined 64% from its peak. Patterson Companies, a dental and veterinary supply distributor foundational to dental practices, agreed to be acquired for $4.1 billion. Hologic's $18.3 billion take-private and R1 RCM's $8.9 billion acquisition highlight the breadth. In each case, public equity markets were offering these businesses at valuations that appeared disconnected from sustainable cash flow. PE sponsors saw opportunity.

For dental, the parallel is emerging: high-quality DSO platforms trading below 8-9x EBITDA multiples represent value to sponsors with multi-year hold horizons. As public healthcare valuations compress further, expect more PE take-privates.

Winners and Losers: The Bifurcation

Park Dental Partners exemplifies the winner's playbook. The company completed its Nasdaq IPO in December 2025 at $13 per share and reported Q4 2025 EPS of $0.30 — beating analyst expectations of -$0.05 by $0.35. That swing is not a statistical anomaly. It reflects operational leverage, disciplined add-on integration, and a platform that reached scale faster than market expectations. Park's trajectory — Minnesota regional DSO to Nasdaq-listed company with 86 practices across three states — is becoming the template for well-capitalized, professionally operated platforms.

Affordable Care exemplifies the opposite. The company is reportedly in financial distress following a $2.7 billion leveraged buyout. Massive leverage combined with slower-than-expected same-store growth and patient acquisition challenges has strained the balance sheet. Unlike Park, which scaled through acquisitions and efficiency gains, Affordable Care is scaling toward a debt wall.

The bifurcation is stark: well-capitalized DSOs with 15%+ revenue growth and disciplined leverage are thriving and reaching public markets. Over-leveraged platforms with single-digit growth and 4-5x debt multiples are in distress. For practice owners considering affiliation, that divergence matters enormously. Joining a strong platform provides access to growth capital, operational excellence, and eventual exit optionality. Joining an over-leveraged platform exposes you to balance sheet risk and potential fire-sale outcomes.

What This Means for Practice Owners

If you own one to three locations, you are a target. PE-backed DSOs and regional platforms are actively hunting for your practice. The thesis is straightforward: your practice probably generates $150-400K in annual EBITDA. At 6-8x EBITDA, that values a single-location practice at $900K-$3.2 million — an attractive add-on price point for platforms seeking to increase scale.

Understand your walk-away price before you receive an offer. Calculate adjusted EBITDA (removing owner W-2, excessive discretionary spending, and one-time items). A practice generating $250K in adjusted EBITDA will likely be approached at 6-7x, or $1.5-1.75 million. Know that multiple. When a DSO tells you your practice is valued at $2.2 million, you should immediately know whether that represents 8x or 10x your true EBITDA — and whether it is above or below market.

If you are considering affiliation, screen for platform quality. Examine the sponsor's other holdings. Check whether the platform is overleveraged (4x+ debt multiples are concerning; 2-3x is conservative). Most importantly, understand the incentive structure: does the platform make money by acquiring you at low multiples and cutting costs, or by growing your practice and earning recurring management fees?

If you are thinking about staying independent, accept what that requires. Independence in 2026 means competing against platforms with 10-30% cost advantages in procurement and access to capital at lower rates than you can secure. It means recruiting in a market where DSOs can offer multi-location schedules, career paths, and signing bonuses. Independence is not impossible — but it is structurally harder than it was five years ago and will be harder still in five years.

What Comes Next

The majority of healthcare leaders plan to pursue additional M&A in 2026. That translates to continued acquisition momentum in dental. Dry powder remains abundant. DSO penetration is still sub-40% in most markets. The mechanics of consolidation have not yet reached saturation.

Watch for three developments. First, more DSO IPOs as platforms achieve scale — Park Dental proved the template works. Second, increased PE sponsor turnover as aging capital deploys and cycles through exits. Third, potential consolidation slowdown if interest rates remain elevated and payer reimbursement compresses further, reducing the cash flow available to service leverage on add-on acquisitions.

The $191 billion healthcare PE wave is not slowing. It is accelerating. For practice owners, the message is clear: understand your EBITDA, know your market, and decide actively whether to build, affiliate, or defend. Your optionality is shrinking, not expanding. Decide now.